Indeed, we focused on miR-200c-3p (from now on referred to as miR-200c), which is predicted to target NRP1 with a percentile score of 68% with 7-nucleotide complementarity (Fig. 5a), since it has been previously identified as an inducer of sensitivity against various anti-cancer agents [52], and its low expression has been implicated in paclitaxel resistance in OC [51]. The gene discussed is NRP1; the disease is cancer.